Johnson & Johnson(J & J) prepares for the future.
If Pfizer should establish itself as the new world number one in pharmacy, on the strength of its successes in the battle against the Covid, the title holder intends to defend its rank.
Joaquin Duato, who took over the reins of the American laboratory on January 1, has just unveiled his ambitions at the JPMorgan conference, the sector's annual high mass.
Read also
Unilever displays an ogre appetite for consumer health
J & J, whose anti-Covid vaccine is one of the only approved in Europe and the United States, is at a turning point in its history.
The group announced in November its split into two listed companies within 18 to 24 months.
Exit hygiene products and non-prescription drugs (Band-Aid dressings, Neutrogena creams, Zyrtec, etc.) which accounted for 15 billion dollars in turnover in 2020 (+1.1%).
The Covid has accentuated the business model divergence between medicines, which generate high margins, which require heavy investment in R&D, and hygiene or OTC products (medicines…
This article is for subscribers only.
You have 71% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for 1€ the first month
I ENJOY IT
Already subscribed?
Login